| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H11NO4 |
| Molecular Weight | 197.1879 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@H](CC1=CC(O)=C(O)C=C1)C(O)=O
InChI
InChIKey=WTDRDQBEARUVNC-ZCFIWIBFSA-N
InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m1/s1
| Molecular Formula | C9H11NO4 |
| Molecular Weight | 197.1879 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
The D-form of dihydroxyphenylalanine (D-dopa) is a less physiologic activity than the L-form. D-dopa can be converted to the active L form during unidirectional chiral inversion, at first, oxidatively deaminated by D-amino acid oxidase to its alpha-keto acid and then transaminated by dopa transaminase to L-dopa. D-dopa is commonly used experimentally to determine whether the pharmacological effects of levodopa are stereospecific.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
